VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit – Benzinga
|
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Benzinga VBI-1901 is a novel immunotherapy developed using VBI's eVLP technology to target CMV-positive (CMV+) tumors, including glioblastoma multiforme (GBM), the company's lead immuno-oncology program. Dr. Anderson will present data in animal models … |
